CJC-1295 vs AOD-9604: What the Research Compares

The short version

CJC-1295 and AOD-9604 are two distinct synthetic peptides that are frequently mentioned together because both relate to the growth hormone axis. They are not the same molecule, they are not alternative names for one another, and they were developed with different research aims. No published trial has compared them directly against each other in the same population, so any comparison has to be assembled from two separate and largely preliminary evidence bases. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a specific compound, condition or treatment.

Are the names overlapping or confused?

The two names are sometimes grouped under headings such as "growth hormone peptides," which is where the confusion starts. That grouping is loose. CJC-1295 is generally described in the literature as a modified analogue of growth hormone releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Two forms are commonly discussed: a version with a drug affinity complex, often written as CJC-1295 with DAC, and a version without it, which is sometimes labelled modified GRF 1-29 and is structurally closer to sermorelin.

AOD-9604 sits in a different structural category. It is described as a synthetic peptide corresponding to the C-terminal region of the human growth hormone molecule, developed on the premise that this fragment might retain metabolic activity associated with the parent hormone without the full hormonal profile. In other words, CJC-1295 is positioned upstream, as a releasing signal, while AOD-9604 is positioned as a fragment of the hormone itself studied mainly for metabolic endpoints. The names are not synonyms, and material describing them as the same product is describing something the published literature does not support.

Side by side at a glance

Head to head evidence: what exists

There is no direct comparison. A search of the published record does not turn up a randomised, controlled or even open label study in which CJC-1295 and AOD-9604 were administered to comparable groups and measured against shared endpoints. That absence matters more than it might appear. Without a shared protocol, shared population and shared outcome measures, any claim that one peptide outperformed the other on fat loss, recovery, strength or body composition is not drawn from evidence; it is drawn from inference across unrelated studies with different designs.

What exists instead is review level coverage of the broader peptide category. A 2026 review in Sports Medicine examined the safety and efficacy of approved and unapproved peptide therapies used for musculoskeletal injuries and athletic performance, and reported that the unapproved members of this category carried marketing and use patterns that were not matched by controlled human evidence (PMID 41966639). A 2026 review in JAAOS Global Research and Reviews covered therapeutic peptides in orthopaedics and reported that applications remained promising in principle while facing substantial translational and regulatory challenges (PMID 41490200). Neither review was structured as a head to head comparison of these two specific compounds.

What published work measured for CJC-1295

Research interest in CJC-1295 has centred on the pharmacological question of whether a modified growth hormone releasing hormone analogue can produce a sustained increase in endogenous growth hormone secretion rather than supplying growth hormone directly. The drug affinity complex modification is the feature most often discussed, because it was designed to extend circulating duration by binding to serum albumin. The downstream endpoints that follow from that premise include growth hormone and insulin-like growth factor 1 concentrations, and, in applied settings, body composition and recovery measures.

In the review literature available here, CJC-1295 is handled as part of the growth hormone secretagogue grouping rather than as a compound with its own mature clinical dossier. The 2026 Sports Medicine review reported that peptides in this applied performance space were used ahead of the evidence needed to characterise their safety and efficacy properly (PMID 41966639). Readers looking for compound level detail on this peptide will find it collected on the dedicated learn page linked below.

What published work measured for AOD-9604

AOD-9604 was developed within obesity research, and the endpoints that shaped its early study programme were metabolic: body weight, fat mass and markers of lipid metabolism. The underlying hypothesis was that a fragment of the growth hormone molecule could influence fat metabolism without the growth promoting and glucose related effects associated with full length growth hormone. Later interest extended toward cartilage and joint tissue, which is why the compound appears in orthopaedic and musculoskeletal discussions rather than only in metabolic ones.

The 2026 orthopaedic peptide review reported that therapeutic peptides in this field faced recurring challenges around delivery, evidence quality and regulatory pathway before any routine clinical application could be considered (PMID 41490200). That framing applies to fragment peptides studied for joint and soft tissue endpoints as much as it applies to the rest of the category.

Regulatory status compared

Neither compound is an approved prescription drug product in the United States. Both are commonly supplied under research use only labelling, which is a statement about the intended use of the material and not a safety or quality certification. Compounding status for peptides has shifted over time as regulators have reviewed bulk substance nominations, and the practical consequence is that availability in one setting does not imply the same status in another.

Review literature treats this status directly. The 2026 Sports Medicine review separated approved from unapproved peptide therapies precisely because that distinction changes what can be said about safety and efficacy (PMID 41966639). For sport, a separate consideration applies: a 2014 review in Expert Review of Proteomics described the analytical status of detecting peptidic drugs, drug candidates and analogs in doping control and reported that detection methods had to be developed for substances that were never approved as medicines (PMID 25382550). Anti-doping rules are set by sporting bodies and change over time, so status under any particular code is a matter for the current published prohibited list rather than for a general education page.

Safety and Adverse Events: What Studies Report

Comparative safety data between these two peptides does not exist, because no study has run them side by side. What the review literature offers is a category level assessment. The 2026 Sports Medicine review assessed safety alongside efficacy for approved and unapproved peptide therapies in musculoskeletal and athletic performance use and reported that the evidence supporting unapproved agents was insufficient to characterise their risk profile with confidence (PMID 41966639). The 2026 orthopaedic review similarly reported that challenges in the field included the gap between preclinical signal and demonstrated clinical benefit and safety (PMID 41490200).

Two practical implications follow. First, an absence of reported adverse events in a small early phase study is not the same as a demonstrated safety record, because small studies detect only common events. Second, product quality is a separate variable from molecular pharmacology: analytical work in the doping control field has repeatedly had to characterise peptide materials of uncertain composition, which is part of why detection and identification methods received dedicated review attention (PMID 25382550).

How to read comparisons like this one

• Check whether the comparison is direct. If two compounds were never studied together, a stated ranking is an opinion layered on top of unrelated datasets.
• Check the species and the endpoint. A rodent metabolic endpoint and a human performance endpoint are not the same claim, and reviews of the field reported that translation between them remains a central difficulty (PMID 41490200).
• Check the regulatory framing. Approved and unapproved peptides are assessed differently, a distinction drawn explicitly in recent review work (PMID 41966639).
• Check who is making the claim. Marketing copy and peer reviewed literature use the same compound names for very different purposes.

Bottom line

CJC-1295 and AOD-9604 are different peptides with different structural origins, different research histories and different primary endpoints, and no published head to head trial compares them. The reviews available for this page reported that unapproved peptides in musculoskeletal, metabolic and performance settings are used ahead of the controlled human evidence needed to judge them (PMID 41966639, PMID 41490200). A comparison page cannot resolve that gap, and nothing here identifies a preferred option.

Related reading

• CJC-1295: what the literature describes
• AOD-9604: what the literature describes

References

• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (JAAOS Global Research and Reviews, 2026)
• Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions (Expert Review of Proteomics, 2014)